– USA, AZ – Picard Medical, Inc. (NYSE American: PMI), parent company of SynCardia Systems LLC, maker of the world’s first U.S. and Canadian commercially-approved total artificial heart, announced the appointments of Sam Van and George Ye to its Board of Directors.
About Sam Van
Sam Van is the founder and CEO of SRO Partners. He previously served as Head of Advisory Services and SVP of Freedom U.S. Markets, a division of Freedom Holding Corp. (Nasdaq: FRHC), and as President and Director of Deltec Investment Adviser Limited.
Earlier in his career, Sam Van held senior leadership positions at the NYSE, including Director of International Listings, where he originated more than 60 new listings, and Senior Examiner in NYSE Regulation. He has also served on the boards of Reed’s Inc., Relm Insurance Limited (Bermuda), and Phoenix Motor, Inc.
Sam Van began his career as an examiner with FINRA.
Sam Van earned an MBA from Cornell University’s Johnson Graduate School of Management and a BS in Finance from St. John’s University.
About George Ye
George Ye is a seasoned executive with extensive leadership experience in the medical device industry. He served in a variety of senior roles at Edwards Lifesciences (NYSE: EW), including SVP and GM for the Greater China Region, VP and GM for Japan Surgical, and Senior Director for Japan and Asia Pacific Strategy.
Before Edwards, George Ye held leadership positions at Abbott Laboratories and Johnson & Johnson, where he built a strong track record across global markets.
George Ye holds a Bachelor of Science in Chemical Engineering and an MBA, both from Northwestern University.
About Picard Medical, Inc.
Picard Medical, Inc. is the parent company of SynCardia Systems, LLC, the Tucson, Arizona–based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart, an implantable system that assumes the full functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the SynCardia Total Artificial Heart is the most widely used and extensively studied artificial heart in the world.
For more information : https://www.syncardia.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.